Squamous cell lung carcinoma
Therapeutic area
Oncology
Rare disease
No
- Definition
- A carcinoma arising from squamous bronchial epithelial cells. It may be keratinizing or non-keratinizing. Keratinizing squamous cell carcinoma is characterized by the presence of keratinization, pearl formation, and/or intercellular bridges. Non-keratinizing squamous cell carcinoma is characterized by the absence of keratinization, pearl formation, and intercellular bridges. Cigarette smoking and arsenic exposure are strongly associated with squamous cell lung carcinoma.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Squamous cell lung carcinoma
- Therapeutic area
- Oncology
- squamous cell lung carcinoma
- epidermoid cell carcinoma of lung
- epidermoid cell carcinoma of the lung
- epidermoid cell lung carcinoma
- lung squamous cell carcinoma
- squamous cell carcinoma of lung
- squamous cell carcinoma of the lung
- squamous cell lung cancer
- squamous cell lung carcinoma
- Severity
- Severe
- Oncology
- Pulmonology
- MONDO ID
- MONDO:0005097
- Parent condition
- MONDO:0005096
Related records
Broader conditions (22)
- Cancer
- Cancer or benign tumor
- Carcinoma
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Epithelial neoplasm
- Human disease
- Lower respiratory tract disorder
- Lung cancer
- Lung carcinoma
- Lung disorder
- Lung neoplasm
- Neoplasm
- Neoplasm of thorax
- Neoplastic disease or syndrome
- Respiratory system cancer
- Respiratory system disorder
- Respiratory tract neoplasm
- Squamous cell carcinoma
Narrower conditions (3)
- Adenosquamous lung carcinoma
- Lung occult squamous cell carcinoma
- Non-small cell squamous lung carcinoma
Trials (116)
- A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
- A Non-interventional Study With Advanced Lung Squamous Cell Carcinoma
- A Phase 1 Study in Participants With Advanced Cancer
- A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
- A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
- A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer
- A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers
- A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom
- A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung Cancer
- A Study of ZEN003694 in People With Squamous Cell Lung Cancer
- A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy
- A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC
- Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care
- An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)
- An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Cancer
- Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma
- Apatinib for Advanced Lung Squmamous Carcinoma
- APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch
Approved drugs (2)
Drugs in development (59)
- Aldesleukin Phase 1
- Apatorsen Phase 2
- Auranofin Phase 1
- Bevacizumab Phase 2
- Bleomycin A6 Phase 2
- Camrelizumab Phase 3
- Carboplatin Phase 3
- Cisplatin Phase 3
- Clarithromycin Phase 2
- Cyclophosphamide Phase 3
- Dasatinib anhydrous Phase 2
- Dexamethasone Phase 2
- Docetaxel Phase 3
- Durvalumab Phase 3
- Erdafitinib Phase 2
- Erlotinib hydrochloride Phase 2
- Etoposide Phase 3
- Fexagratinib Phase 2
- Fludarabine Phase 1
- Gefitinib Phase 3